6 results about "CXCL10" patented technology

The application belongs to the technical field of biological medicine, and particularly relates to the use of SH2 domain-containing protein tyrosine phosphatase 1 (SHP1) in the preparation of a drug for treating chronic pain, in particular to the use of SHP1 in the preparation of a drug for treating chronic pain by regulating the morphology of spinal cord astrocytes, the integrity of the blood-spinal cord barrier and the STAT1-CXCL10-CXCR3 neuroimmune signal axis, and a chronic pain treatment strategy based on the signal axis. The application first discloses that SHP1 in spinal cord astrocytes directly dephosphorylates STAT1, inhibits the transcription of CXCL10 and the subsequent infiltration of T lymphocytes into the spinal cord, and discloses the core analgesic mechanism, thereby establishing SHP1 as a new target for treating chronic pain, and opening up a new way for the precise treatment of clinical chronic pain, especially neuropathic pain.

Provided herein are methods and immune biomarkers for identifying multiple sclerosis (MS) progression and treatment options. Materials and methods for prognosing, staging, and monitoring MS in a sample are also provided, including methods for determining a subject as at risk for developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of a subject, and administering a pharmaceutically effective amount of a therapy (e.g., trebrutinib and potentially one or more additional therapies, e.g., an anti-CD20 therapy) to the subject.

Provided herein are methods and immune biomarkers for identifying progression and therapeutic selection of multiple sclerosis (MS). Also provided are materials and methods for prognosis, staging, and monitoring of MS in a sample, and including methods of determining that a subject is at risk of developing MS. The method comprises detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of the subject; and administering to the subject a pharmaceutically effective amount of a treatment (e.g., tobutinib and potentially one or more additional therapies, such as an anti-CD20 therapy).

Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity, including against multidrug-resistant bacteria. In some embodiments, the peptides include amino acid sequences as set forth in any of SEQ ID NOs: 2-151, modified peptides, fragments, and conjugates thereof, and any combination thereof. The peptides, modified peptides, fragments, and conjugates can be polymer-functionalized, encapsulated in a particle, embedded in and / or on a solid support, impregnated in a dressing, and / or is formulated for use in a nebulizer, for topical administration, and / or for systemic administration. Also provided are medical devices having an antibacterial agent embedded in and / or associated with a support layer, and methods for inhibiting growth of and / or killing bacteria, for treating or preventing community and / or nosocomial infections, for treating bacterial infections present in wounds, for treating pulmonary infections, for treating or preventing systemic bacterial infections, and for combination therapies with conventional antibiotics.

Disclosed herein are methods of diagnosing a subject for a risk of developing severe coronavirus disease as correlated to the presence of IgA anti-IFN-alpha autoantibodies. In certain embodiments, the methods include the use of fluorescent beads that are used to analyze the presence of IgA1 and / or IgA2 anti-IFN-alpha autoantibodies and simultaneous measurement of IFN-α and CXCL10 in the same nasal sample. In certain embodiments, methods further comprise reporting the diagnosis to the subject or medical professional. In certain embodiment, methods further comprise administering a pharmaceutical agent to the subject.